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Introduction	and	Basics	of	Channels	and	Transporters
Beat Ernst
In the first lecture Beat Ernst, University of Basel, provided 
an overview about structure and function of membrane transport 
proteins. Energy coupling is an important aspect of these transport 
systems. Uniporters simply facilitate passive diffusion as transport 
follows the direction of a concentration gradient. Primary, second-
ary and tertiary active transporters, on the other hand, move ions or 
neutral molecules against a concentration gradient (Fig. 2) with the 
help of energy provided either by ATP hydrolysis or by the down-
hill movement of an ion coupled to the uphill movement of the 
respective solute. Glucose transporters GLUT1-12 that function in 
numerous organs are examples of uniporters transporting glucose 
along a concentration gradient. Sodium-dependent glucose co-
transporters (SGLT) that are responsible for glucose transport in 
the small intestine, kidney and liver and peptide transporters which 
facilitate the uptake of peptides in the small intestine (PEPT1) and 
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Abstract: During a half-day symposium, the topic ‘Channels and 
Transporters’ was covered with five lectures, including a presen-
tation on ‘Introduction and Basics of Channels and Transporters’ 
by Beat Ernst, lectures on structure, function and physiology of 
channels and transporters (‘The Structural Basis for Ion Conduc-
tion and Gating in Pentameric Ligand-Gated Ion Channels’ by 
Raimund Dutzler and ‘Uptake and Efflux Transporters for Endog-
enous Substances and for Drugs’ by Dietrich Keppler), and a case 
study lecture on ‘Avosentan’ by Werner Neidhart. The program 
was completed by Matthias Hediger who introduced to the audi-
ence the National Center of Competence in Research (NCCR)-
TransCure in his lecture entitled ‘From Transport Physiology to 
Identification of Therapeutic Targets’.
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Introduction
Ligand- and voltage-gated ion channels have been known for de-
cades to be involved in ion transport, electrical conductance and 
maintenance or modulation of membrane potentials, and have thus 
always had some relevance as targets of marketed and experimen-
tal drugs. The in-depth structural and functional understanding of 
specific channel types, however, became available only in recent 
years. Transporters represent even more complex molecular ma-
chineries: a plethora of membrane transporters for endogenous 
substances and drugs exist. Based on their transport mechanisms 
they are classified as uniporters, symporters, antiporters or as uni-
directional membrane ATPases (efflux pumps). Many of them 
have been identified and characterized over the recent years in the 
membranes of the intestine, liver, kidney, and at the blood–brain 
barrier. A steadily increasing amount of structural and functional 
information about transporters is becoming available. Many drugs 
interact with several of them during their path through the body, but 
it is still rather the exception than the rule that drugs directly target 
transporters or that interaction with specific transporters is actively 
pursued during a drug development program.
During the Mini-Symposium, the five speakers (Fig. 1) pro-
vided insights into basic understanding, structure and function of 
ion-channels and transporters, as well as on the National Trans-
porter Research Programs; a drug development case study com-
pleted the event.
Fig. 1. Dietrich Keppler, Matthias Hediger, Raimund Dutzler, Werner 
Neidhart and Beat Ernst.
Fig. 2. Schematic representation of uniporters that facilitate passive 
diffusion and of primary, secondary and tertiary active transporters.
ConferenCe report  CHIMIA 2010, 64, No. 9  663
promote re-absorption of peptides in the proximal tubuli of the kid-
ney (PEPT2) represent examples of secondary active transporters.
Ion channels catalyze the selective and rapid diffusion of ions 
down their electrochemical potential. These proteins consist of 
a transmembrane pore with a narrow selectivity filter and a gate 
that opens and closes the ion permeation path (Fig. 3). Channels 
are classified according to their mode of gating: Voltage-gated 
Na+, K+, Cl-, Ca++ channels are gated in response to changes in 
the transmembrane electric field, but there exist also examples of 
non-gated members within the respective families. Ligand-gated 
nicotinic ACh-receptors, NMDA-receptors, and GABAA-receptors 
are gated by their respective ligands acetylcholine, glutamate and 
GABA. The M2-protein (Influenza A) represents an example of 
a proton-gated channel whereas mechanical stimuli gate certain 
bacterial channels. In other cases ion channels can be regulated in 
response to signals received from non ionotropic neurotransmitter 
receptors of the GPCR family such as muscarinic ACh-receptors, 
serotonin-receptors and GABAB receptors. 
Ion channels have been widely used as drug targets: potas-
sium channel blockers like Glibenclamide and Tolbutamide are 
well-established antidiabetics. Sodium channel blockers Procaine, 
Lidocaine and Sotalole act as local anesthetics. Calcium chan-
nel blockers Nifedipine, Verapamil and Diltiazeme are highly ef-
fective antihypertensives, and Amantadine and Rimantadine are 
potent blockers of viral M2-channels. ‘Moderne Pharmakokine-
tik – Transport durch Membranen’ by Beat Ernst and Alexander 
Vögtli[1] is recommended for further reading.
The	Structural	Basis	for	Ion	Conduction	and	Gating	in	
Pentameric	Ligand-Gated	Ion	Channels
Raimund Dutzler 
Raimund Dutzler from the University of Zurich discussed 
structural and functional properties obtained from X-ray struc-
tures of two prokaryotic pentameric ligand-gated ion channels, 
which share the overall architecture of their eukaryotic coun-
terparts with conservation in functionally important residues. 
Although both structures are overall similar they show different 
conformations of the ion conduction pore. The structure of the 
ion channel from Erwinia chrysanthemi (ELIC) depicts a non-
conducting state of the channel with a narrow transmembrane 
pore that is interrupted by conserved hydrophobic residues.[2] A 
second structure from a homologous protein from the cyanobac-
terium Gloebacter violaceus (GLIC) has revealed a conducting 
conformation where the hydrophobic constriction is removed.[3] 
The two structures thus suggest a novel gating mechanism for 
the family where pore opening proceeds by structural changes in 
the transmembrane region (Fig. 4). Fig. 5 shows the a2 helices 
defining the pore region in ELIC and GLIC. Assuming that the 
two structures depict the closed and open conformations of the 
ion conducting pore, opening occurs as consequence of ligand 
binding to a site in the extracellular domain. This event causes 
a conformational change in the ligand-binding domain that is 
transmitted to the transmembrane part and triggers a change in 
the tilt of helices a2 and a3 of the pore domain. These helices 
move as a rigid body around an axis that is located about half-
way across the membrane and that runs parallel to its plane. 
As result of this movement the ion permeation path in GLIC 
has opened to a funnel-like aqueous pore, which represents a 
conducting conformation. This pore is wide at its hydrophobic 
extracellular half, it narrows at its hydrophilic intracellular half 
and it contains negatively charged residues at the cytoplasmic 
entry that play an important role for ion-protein interactions (for 
a systematic representation see Fig. 6). This open conformation 
is reversibly inhibited by channel blockers such as the local 
anaesthetic Lidocaine. The Lidocaine binding site is located at 
an extended site in the center of the pore and is likely conserved 
within the cation selective part of the family. The two prokaryo-
tic ion channels thus provide first structural insight into the ion 
permeation and gating mechanisms of pentameric ligand gated 
ion channels, but we should be aware that our understanding of 
channel function is still at an early stage.
Fig. 3. Channel structure with pore, selectivity filter and gate at the inner 
end of the pore.
Hilf RJC & Dutzler R Nature 452 (2008) Hilf RJC & Dutzler R Nature 457 (2009)
Fig. 4. Ribbon representation of ELIC (closed channel conformation) 
and GLIC (open channel conformation) viewed from within the 
membrane with the extracellular solution above and from the 
extracellular side along the pore axis.[2,3] 
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Uptake	and	Efflux	Transporters	for	Endogenous	
Substances	and	for	Drugs
Dietrich Keppler 
The relevance of membrane transporters in humans was the 
focus of the lecture by Dietrich Keppler, German Cancer Research 
Center, Heidelberg. Precise knowledge about localization of spe-
cific transporters and their substrate specificity allows understand-
ing and prediction of uptake and elimination routes in the body. 
Transporters exert their functions at any relevant epithelium all 
over the body, as in the intestine, in hepatocytes, in cholangiocytes, 
in the gallbladder, in kidney proximal tubules, at the blood–brain 
barrier, in the choroid plexus, in the airways, in the placenta, and 
in fetal capillaries. Hepatocyte transporters have been the focus 
of intense research activities for at least two decades. Fig. 7 sum-
marizes relevant transporters in human hepatocytes together with 
their year of first localization. 
Human genetic variants as well as knockout animal models 
have proven to be very helpful in elucidating the role of trans-
porters in drug disposition, e.g. the hereditary deficiency of the 
human bile salt export pump (ABCB11) in familial intrahepatic 
cholestasis (PFIC2), or Mdr1 p-glycoprotein deficiency in Mdr1a 
knockout mice and Collie dogs resulting in an about 100-fold in-
creased sensitivity to the centrally neurotoxic pesticide Ivermectin 
(due to the absence of the Mdr1 p-glycoprotein which prevents in 
control animals Ivermectin from crossing the blood brain barrier).
Monolayers of double-transfected polarized cells provide use-
ful systems to study the transport of endogenous substances, drugs, 
and toxins (Fig. 8). In such systems, vectorial transport of sub-
strates of both transporters (uptake and efflux transporters) can be 
observed at a much higher rate than in non-transfected or single-
transfected cells.
Frequently, xenobiotics and drugs are substrates for several dif-
ferent transport proteins: a list of the most relevant transport proteins 
includes OATP1B1, OATP1B3, OATP2B1, OAT1, OAT3, OCT2, 
OCT1 for cellular uptake; and MDR1 P-gp (ABCB1), BCRP 
(ABCG2), BSEP (ABCB11), MRP2 (ABCC2), MRP4 (ABCC4) 
GLICELIC
hydrophobic
polar
charged
Fig. 5. View of the a2 helices defining the pore regions in ELIC (left) 
and GLIC (right). The front subunit has been removed for clarity. The 
molecular surface is shown as white mesh. 
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Fig. 6. Schematic representation of the pore in the open GLIC channel 
with a divalent cation (blue) bound to the narrow intracellular part, the 
selectivity filter of the channel and a positively charged pore blocker 
bound in the center of the membrane (a). View of the a2 helices 
defining the pore region in the open GLIC channel with a 4-bromo-
lidocaine molecule bound to an extended site in the center of the 
membrane (b). 
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Fig. 7. Human Hepatocyte Transporters: overview and year of first 
localization.
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Y. Cui, J. König, D. Keppler, Mol. Pharmacol., 2001
Fig. 8. Double-transfected MDCKII Cells: double-transfected Madin-
Darby canine kidney (MDCK) cell line permanently expressing a 
recombinant uptake transporter for organic anions in the basolateral 
membrane and an ATP-dependent export pump for anionic conjugates 
in the apical membrane.
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Clinical leads with threshold properties - ETA potency, PK, in vivo cholestasis
ETA-R: 1.8 nM, pA2 8.4
PK o-F: 90% (acid: 22%) (rat)
In vivo efficacy: Doca 3+
Cholestasis index: 1.5
RO0670565
ETA-R 1.4 nM, pA2: 8.6
ETB-R 0.6 M
PK o-F: 78-100% (rat)
In vivo efficacy: Doca 3+
Cholestasis index: 12.5
ETA-R: 1nM, pA2: 8.2
PK o-F: 20% (rat)
Lead compoud
ETA-R: 1.6 nM, pA2: 8.8
PL exposures >> bos (5mg/kg, rat)
In vivo efficacy: Doca 2+
Cholestasis index: 17
ETA-R: 1.5 nM, pA2: 8.1
PK o-F: 54% (rat)
In vivo efficacy: Doca 3+
Cholestasis index: 4.3
ETA-R: 2.5 nM, pA2: 8.1
PK o-F: 70 % (rat)
In vivo efficacy: Dahl 3+
Cholestasis index: 50
RO0485695:
Cholestasis index: 0.09
In vivo efficacy estimate: Doca: 1+/2+/ 3+
BPLow.: 5-10 /10-15/>20 mmHg (1-3 mg/kg)
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Fig. 12. The compound optimization path leading to RO0670565, 
Avosentan.
for cellular efflux. Detailed knowledge of the interactions with all 
of them is indispensable for in-depth understanding of uptake and 
elimination routes in the body. For a recent review see Giacomini 
et al., ‘Membrane transporters in drug development’.[4]
From	Transport	Physiology	to	Identification	of	
Therapeutic	Targets
Matthias Hediger 
Matthias Hediger, University of Bern, gave a brief overview 
about the National Center of Competence in Research (NCCR)-
TransCure, a joint research project that was recently funded by 
the Swiss National Science Foundation (SNSF). Matthias Hedi-
ger has identified and characterized novel transporters of various 
classes. These include the Na+glucose cotransporter SGLT1 and 
the intestinal oligopeptide transporter PEPT1. Subsequently, he 
has elucidated the physiological, pathological and pharmaceu-
tical aspects of the transporters of interest using a diverse array 
of approaches. The vision of the NCCR-TransCure is to exploit 
excellence in membrane transporter research for the treatment of 
human diseases. Key to success will be a unique research collabo-
ration involving three major disciplines: i) physiology/pathology/
medicine, ii) structural biology and ii) organic chemistry/ligand 
design (Fig. 9). The NCCR-TransCure is composed of 18 scientific 
laboratories from Basel, Bellinzona, Bern, Lausanne and Zurich.
Through research in the field of membrane biology, the NCCR-
TransCure aims to understand the mechanisms of common dis-
eases like diabetes, hypertension, cancer and neurodegenerative 
disorders, and to develop, based on this knowledge, innovative 
therapeutic strategies and novel treatment drugs.
Avosentan	
Werner Neidhart 
In his case study lecture, Werner Neidhart, F. Hoffmann-La 
Roche Ltd, Basel, talked about the identification of Avosentan, an 
endothelin A receptor (ETA-R) selective follow-up compound of 
RO0485695 (Fig. 10). RO0485695 had to be withdrawn from clin-
ical trials after an eight-day clinical phase I study. Liver enzyme 
increase had been observed and blood chemistry data indicated an 
induction of cholestasis through interference with the excretion 
pathway of bile acids as main underlying cause. Impairment of 
bile formation, by blockage of the canalicular bile salt export pump 
NCCR-TransCure Strategy
“TransCure Trias”
Aim: To correct the dysfunction of transport proteins
using specific chemical ligands.
1. Detailed studies of the function of transport proteins and
the defects that lead to pathological changes.
physiology, pathology, medicine
2. Determination of the 3-D architecture of the ligand-binding
sites of the corresponding transport proteins.
structural biology
3. Design and manufacture of specific chemical ligands that
bind to these sites.
chemistry
chemical ligands
Close collaboration between
physicians/ physiologists,
structural biologists and
chemists (“TransCure Trias”) key
to the success of TransCure.
Fig. 9. NCCR-TransCure Strategy: TransCure Trias.
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Fig. 11. Cholestasis & bile acid excretion in hepatocytes demonstrating 
how interference with bile acid excretion can cause liver damage.
Strategy
• Smart screening of threshold compounds for oral bioavailability, ET
database
• Structure-function analysis - Explore molecular determinants
related to key issues: potency, bioavailability, cholestasis liability
Desired profile
• High functional antagonistic potency (~ to RO0485695)
• High oral bioavailability (> 50%)
• Low in vivo liver liabilitiy
Targeted Indications
• Hypertension // Congestive heart failure // Renal
protection
ETA/B-R: 0.7/5 nM
pA2: 9.3 (funct.)
MW665, clogP4.65
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Cholestasis index: 0.09
(Acute in vivo model)
clogPx MW: 32092
Fig. 10. Concept for the identification of an ETA-R selective follow-up 
compound of RO0485695.
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(cBsep), was assumed to be the main culprit; in other words, the in-
tracellular accumulation of cytotoxic bile acids and the subsequent 
cell damage was assumed to be responsible for the observed liver 
enzyme increase (Fig. 11). Compounds with favorable Cholesta-
sis indices [Cholestasis index = ED 50/(d10 + d30) (efficacy vs 
time curve of plasma bile acid increase)] were favored during the 
compound optimization process (Fig. 12) which finally resulted 
in the identification of RO0670565, Avosentan, as the optimized 
compound (Fig. 12, 13).
No sign of liver toxicity in the in vivo rat model of acute cholestasis
Dose response curves for the increment of plasma bile acids increase
10 min. after i.v. administration of RO0670565 and RO0485695
Estimated therapeutic dose
0.5 mg/kg (35 mg/subject)
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Fig. 13. Liver toxicity profile of RO0670565, Avosentan, showing no 
sign of liver toxicity in the in vivo rat model of acute cholestasis.
All preclinical parameters, efficacy, pharmacokinetics, 
cholestasis prediction, and overall toxicity profile translated very 
well into the clinical behavior of the compound, and no liver li-
ability has been observed thus far in humans.
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